Inherited variation in the PARP1 gene and survival from melanoma

We report the association of an inherited variant located upstream of the poly(adenosine diphosphate‐ribose) polymerase 1 (PARP1) gene (rs2249844), with survival in 11 BioGenoMEL melanoma cohorts. The gene encodes a protein involved in a number of cellular processes including single‐strand DNA repair. Survival analysis was conducted for each cohort using proportional hazards regression adjusting for factors known to be associated with survival. Survival was measured as overall survival (OS) and, where available, melanoma‐specific survival (MSS). Results were combined using random effects meta‐analysis. Evidence for a role of the PARP1 protein in melanoma ulceration and survival was investigated by testing gene expression levels taken from formalin‐fixed paraffin‐embedded tumors. A significant association was seen for inheritance of the rarer variant of PARP1, rs2249844 with OS (hazard ratio (HR) = 1.16 per allele, 95% confidence interval (CI) 1.04–1.28, p = 0.005, eleven cohorts) and MSS (HR = 1.20 per allele, 95% CI 1.01–1.39, p = 0.03, eight cohorts). We report bioinformatic data supportive of a functional effect for rs2249844. Higher levels of PARP1 gene expression in tumors were shown to be associated with tumor ulceration and poorer OS.

[1]  D. Schadendorf,et al.  Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study , 2012, Pigment cell & melanoma research.

[2]  G. Argenziano,et al.  Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. , 2005, Human pathology.

[3]  Jeffrey E. Lee,et al.  Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3 , 2011, Nature Genetics.

[4]  S. Puig,et al.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). , 2008, European journal of cancer.

[5]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[6]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[7]  Simon C. Potter,et al.  Mapping cis- and trans-regulatory effects across multiple tissues in twins , 2012, Nature Genetics.

[8]  M. Hottiger,et al.  A Role of Poly (ADP-Ribose) Polymerase in NF- B Transcriptional Activation , 1999 .

[9]  A. West,et al.  Insulators: many functions, many mechanisms. , 2002, Genes & development.

[10]  J. Barrett,et al.  Patterns of Expression of DNA Repair Genes and Relapse From Melanoma , 2010, Clinical Cancer Research.

[11]  Simon C. Potter,et al.  The Architecture of Gene Regulatory Variation across Multiple Human Tissues: The MuTHER Study , 2011, PLoS genetics.

[12]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Manolis Kellis,et al.  HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..

[14]  Peng Yue,et al.  SNPs3D: Candidate gene and SNP selection for association studies , 2006, BMC Bioinformatics.

[15]  A. G. de Herreros,et al.  PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation , 2013, PLoS genetics.

[16]  I. Ellis,et al.  Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma , 2011, Modern Pathology.

[17]  Juri Rappsilber,et al.  A model for transmission of the H3K27me3 epigenetic mark , 2008, Nature Cell Biology.

[18]  J. Yokota,et al.  Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Hottiger,et al.  A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. , 1999, Biological chemistry.

[20]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[21]  V. Lazar,et al.  Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? , 2012, Current opinion in oncology.

[22]  J. Barrett,et al.  Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. , 2009, European journal of cancer.

[23]  E. Smit,et al.  Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy , 2012, Cancer.

[24]  R. Hromas,et al.  Synthetic lethality: exploiting the addiction of cancer to DNA repair. , 2011, Blood.

[25]  Jack A. Taylor,et al.  SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies , 2009, Nucleic Acids Res..

[26]  M. Binder,et al.  Site‐dependent actinic skin damage as risk factor for melanoma in a central European population , 2012, Pigment cell & melanoma research.

[27]  N. Garg,et al.  Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. , 2011, The American journal of pathology.

[28]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[29]  Wyeth W. Wasserman,et al.  JASPAR: an open-access database for eukaryotic transcription factor binding profiles , 2004, Nucleic Acids Res..

[30]  Tsun-Po Yang,et al.  Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies , 2010, Bioinform..

[31]  H. Olsson,et al.  Is the use of sunscreens a risk factor for malignant melanoma? , 1995, Melanoma research.

[32]  D. Bishop,et al.  Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival , 2009, Clinical Cancer Research.

[33]  David Haussler,et al.  ENCODE Data in the UCSC Genome Browser: year 5 update , 2012, Nucleic Acids Res..

[34]  H. Gogas,et al.  A study of a single variant allele (rs1426654) of the pigmentation‐related gene SLC24A5 in Greek subjects , 2009, Experimental dermatology.

[35]  Claus Scheidereit,et al.  A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. , 2009, Molecular cell.

[36]  C. Leonetti,et al.  Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. , 2007, European journal of cancer.

[37]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[38]  David G. Castner,et al.  Microplate-based chromatin immunoprecipitation method, Matrix ChIP: a platform to study signaling of complex genomic events , 2008, Nucleic acids research.

[39]  T. Spector,et al.  Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi , 2009, Nature Genetics.

[40]  M. Loh,et al.  Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia , 2011, Nature Genetics.

[41]  J. Malvehy,et al.  Melanomas detected in a follow-up program compared with melanomas referred to a melanoma unit. , 2011, Archives of dermatology.

[42]  K. Bille,et al.  Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). , 2011, Genes & development.

[43]  D. Schadendorf,et al.  Melanocortin receptor 1 variants and melanoma risk: A study of 2 European populations , 2009, International journal of cancer.

[44]  Hiroshi Suzuki,et al.  Parp1-deficiency induces differentiation of ES cells into trophoblast derivatives. , 2003, Developmental biology.

[45]  Joseph K. Pickrell,et al.  DNaseI sensitivity QTLs are a major determinant of human expression variation , 2011, Nature.

[46]  S. Elgin,et al.  Putting Boundaries on Silence , 1999, Cell.

[47]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[48]  J. Yélamos,et al.  PARP-1 and PARP-2: New players in tumour development. , 2011, American journal of cancer research.